A pre-clinical biopharmaceutical company dedicated to precision cardiology through targeted RNA therapeutics designed to ...

French pharma Sanofi (Euronext: SAN) has agreed to license the experimental drug rovadicitinib from China’s Sino Biop (HKEX: 1177), paying $135 million upfront for exclusive development and ...

Swiss drugmaker Roche (ROG: SIX) has released findings from a global survey suggesting that the unpredictability of diabetes ...

Shares of Hansa Biopharma rose nearly 7% to 32.98 kronor, after the Swedish company announced that the Food and Drug ...

Canada based clinical-stage pharma Helus Pharma today announced top-line results from a Phase II signal detection study ...

Germany’s Merck KGaA reported broadly stable full-year 2025 results, with modest top-line pressure from currency headwinds ...

USA-based Biologos, an ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today ...

Chinese cell therapy developer Lemang Biotech has raised nearly 200 million yuan ($28 million) in fresh financing to advance ...

German family-owned pain medicines specialist Grünenthal has entered into collaboration with BCWorld Pharm for the exclusive South Korean rights to Qutenza (capsaicin), a topical, non-systemic, ...

I've worked with pharmaceutical companies for years, and one pattern keeps repeating: the most significant environmental, health, and safety (EHS) risks are rarely dramatic. They sit in routine ...

Medicus Pharma has announced top-line results from its Phase II study of doxorubicin microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin.

Chinese biopharma Hutchmed today reported a net income of $456.9 million for the year ended December 31, 2025, a significant increase from $37.7 million in the prior year, largely driven by a $415.8 ...